Ulixacaltamide not checked
Praxis Precision Medicines · PRAX-944
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Essential Tremor
- Main trialPhase 3
- “The goal of this clinical study is to compare ulixacaltamide and placebo treatment in essential tremor. The main question it aims to answer is: • Is ulixacaltamide a safe and efficacious treatment for patients with essential tremor? Participants will be asked to participate in one of two clinical studies where they will be treated with either ulixacaltamide or placebo for a period of up to 12 weeks. After the controlled study completion, they will be eligible to participate in a long-term, open-label safety study (LTSS) and be treated with ulixacaltamide. Participants are eligible to enroll…”In the company’s words, NCT06087276 on ClinicalTrials.gov
- Other names
- PRAX-944
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 10 Oct 2025 | Essential 3 - Decentralized, Phase 3 Study Evaluating the Safety and Efficacy of Ulixacaltamide in Essential Tremor (ET) | |
| Phase 2Completed | 24 Mar 2022 | A Clinical Trial of PRAX-944 in Participants With Essential Tremor | |
| Phase 2Completed | 9 Feb 2023 | A Clinical Trial of 2 Doses of PRAX-944 in Participants With Essential Tremor |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026